The European Commission Signs an Agreement with Roche and Merck to Supply their COVID-19 Therapies in EU

 The European Commission Signs an Agreement with Roche and Merck to Supply their COVID-19 Therapies in EU

The European Commission Signs an Agreement with Roche and Merck to Supply their COVID-19 Therapies in EU

Shots:

  • The EC has signed an agreement to supply Roche’s RoActemra and Merck’s Rebif in 27 EU member states willing to buy the therapies to combat the pandemic. The agreement follows requests from EU states in May to acquire the two drugs having the potential to target COVID-19
  • In a discussion with EC, Roche has committed to meet the need for eligible patients with COVID-19 associated pneumonia in the EU & across the globe in an equitable and sustainable manner. On Jul 08, 2020, EC asked Merck to be prepared to supply Rebif in EU states
  • Roche is evaluating RoActemra in 330 COVID -19 patients and also assessing it in combination with Gilead’s Remdesivir while Rebif was developed by Serono before Merck acquired the company

Click here to read full press release/ article | Ref: Reuters | Image: Twitter

Related News: Roche to Initiate P-III COVACTA Study of Actemra/RoActemra in Hospitalized Patients with Severe Covid-19 Pneumonia in Collaboration with BARDA

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post